|
US Contrast Enhanced Study as an Imaging Biomarker of
Anti-cancer Drug Treatment: Preliminary Study with
Paclitaxel and a Xenograft Mouse Tumor Model |
|
Hak Jong Lee, MD1 Sung Il Hwang, MD1, Jonghoe Byun, MD2,
Hoon Young Kong, MD2, Hyun Sook Jung, PhD1, Mira Kang, RN1 |
|
1Department of Radiology, Seoul National University College of Medicine and Seoul National
University Bundang Hostpital
2Department of Molecular Biology, Dankook University |
|
Purpose: We wanted to assess tumor angiogenesis of human prostate cancer cells
(PC3) implanted in mice before and after paclitaxel injection via contrast-enhanced
ultrasonography (CEUS).
Materials and Methods: Twelve mice were injected with human prostate cancer
cells (PC3) on the back or hind limbs. The mice were grouped into two groups; one
was the paclitaxel treated group (n = 6) and the other was the control group, which
was treated with normal saline (n = 6). Before injection of paclitaxel into the peritoneal
cavity, baseline CEUS was performed by the administration of 500 μl (1×108
microbubbles) of contrast agent. The area under the curve (AUC) up to 50 seconds
after contrast injection was derived from the time-intensity curves. After injection of
paclitaxel or saline, one week follow up CEUS studies were performed. The changes
of the tumor volume and the AUC in both two groups were evaluated. After CEUS, the
mice were sacrificed and the microvessel density (MVD) was compared.
Results: In the paclitaxel treated group, the AUC from CEUS showed a significant
decrease one week after paclitaxel administration (p = 0.03), even though the tumor
volume showed no significant changes (p = 0.116). In the control group, there was no
significant decrease of the AUC (p = 0.173). Pathologically, there was a significant difference
of microvessel density in both groups (p = 0.002).
Conclusion: The AUC from the time intensity curve derived from CEUS showed
early change in response to the anti-cancer drug treatment in advance of a tumor size
response. The findings of CEUS could be an imaging biomarker for assessing the
tumor response to anti-cancer drug treatment. |
|
Keyword : Ultrasound; Contrast agent; Angiogenesis; Anti-cancer treatment; |
|
pdf파일 : 147-154이학종.pdf
|
|